Recombinant Rhesus Macaque TP53 Protein, His (Fc)-Avi-tagged

• Cat.No.: TP53-4724R
• Product Overview: Recombinant Rhesus Macaque TP53 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Rhesus Macaque
• Tag: His (Fc)-Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: TP53 tumor protein p53 [ Macaca mulatta (Rhesus monkey) ]
• Official Symbol: TP53
• Synonyms: TP53; cellular tumor antigen p53; P53; tumor suppressor p53
• Gene ID: 716170
• mRNA Refseq: NM_001047151
• Protein Refseq: NP_001040616
• UniProt ID: E3U906

Reviews

02/26/2023

By actively engaging with researchers and understanding their needs, manufacturers can contribute significantly to the success and impact of research involving the TP53 protein.

11/05/2020

This flexibility allows for tailored approaches and provides researchers with more options to study specific aspects of TP53 biology or its interactions with other molecules.

07/24/2017

Manufacturers can provide comprehensive product information, including data on the functionality, stability, and handling of TP53 protein.

Q&As

Can TP53 status be used for cancer risk assessment and screening in individuals with a family history of cancer?

Yes, identifying TP53 mutations in families with a history of early-onset cancers can help identify individuals at high risk for cancer and guide screening and prevention strategies.

What are the challenges in developing targeted therapies for TP53-mutated cancers?

TP53 mutations are highly diverse, making it challenging to develop a one-size-fits-all therapy. Additionally, the p53 pathway is complex, and disrupting it can have unintended consequences.

Can TP53 status influence eligibility for certain clinical trials?

Yes, TP53 mutation status can be a criterion for eligibility in specific clinical trials, especially those testing experimental treatments that may target the p53 pathway.

How might TP53 status affect decisions regarding surgery, chemotherapy, and radiation therapy?

TP53 status can influence treatment decisions. For example, patients with TP53 mutations may require more aggressive treatment approaches or different chemotherapy regimens.

Are there targeted therapies specifically designed for TP53-mutated cancers?

Currently, there are no specific targeted therapies approved solely for TP53-mutated cancers. However, research is ongoing to develop drugs that target the altered p53 pathway.